These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3080832)

  • 1. Cost-benefit analysis of a plateletapheresis program.
    McFarland JG; Larson EB; Hillman RS; Slichter SJ
    Transfusion; 1986; 26(1):91-7. PubMed ID: 3080832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model to determine required pool size for HLA-typed community donor apheresis programs.
    Bolgiano DC; Larson EB; Slichter SJ
    Transfusion; 1989 May; 29(4):306-10. PubMed ID: 2718233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plateletapheresis program. II. Computer selection of HLA compatible donors.
    Jorgensen DW; McFarland JG; Hillman RS; Slichter SJ
    Transfusion; 1984; 24(4):292-8. PubMed ID: 6547791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM; Cannon A; Mitchum EN
    Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.
    Lopez-Plaza I; Weissfeld J; Triulzi DJ
    Transfusion; 1999 Sep; 39(9):925-32. PubMed ID: 10533816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of random-donor platelet concentrates prepared from whole blood units and platelets prepared from single-donor apheresis collections.
    Sloand EM; Yu M; Klein HG
    Transfusion; 1996; 36(11-12):955-9. PubMed ID: 8937403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
    Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to recruit plateletpheresis donors from a registry of HLA-typed, unrelated, bone marrow donors.
    Bolgiano DC; Smith S; Slichter SJ
    Transfusion; 1993 Aug; 33(8):675-8. PubMed ID: 8342236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective cell support by repeat plateletpheresis of related donors on the IBM 2997 cell separator.
    Langley JW; Spiva D; Hendren D; Orrell J
    Am J Clin Pathol; 1981 Aug; 76(2):148-54. PubMed ID: 7270495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single donor platelets: can we afford to use them? Can we afford not to use them?
    Zeger G; Williams CT; Shulman IA
    Transfus Sci; 1997 Dec; 18(4):585-8. PubMed ID: 10178683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusion.
    Zeigler ZR; Shadduck RK; Rosenfeld CS; Mangan KF; Winkelstein A; Oral A; Ramsey GE; Duquesnoy RJ
    Blood; 1987 Nov; 70(5):1433-6. PubMed ID: 2444288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
    Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
    Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of donor platelet count and platelet yield in apheresis products: relevance for emerging issues in platelet transfusion therapy.
    Goodnough LT; Ali S; Despotis G; Dynis M; DiPersio JF
    Vox Sang; 1999; 76(1):43-9. PubMed ID: 9933853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors.
    Benson K; Marks AR; Marshall MJ; Goldstein JD
    Transfusion; 1994 May; 34(5):432-7. PubMed ID: 8191569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood collection and transfusion in the United States in 1999.
    Sullivan MT; Wallace EL
    Transfusion; 2005 Feb; 45(2):141-8. PubMed ID: 15660821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets.
    O'Rafferty C; Rooney G; Hagan R; Woolfson M; O'Donghaile D; Fitzgerald J
    Transfus Med; 2017 Oct; 27 Suppl 5():369-374. PubMed ID: 28393455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients.
    Friedberg RC; Donnelly SF; Mintz PD
    Transfusion; 1994 Mar; 34(3):215-20. PubMed ID: 8146893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoglobin and platelet count effect on platelet yields in plateletpheresis.
    Guerrero-Rivera S; Gutiérrez-Espíndola G; Talavera JO; Meillón-García LA; Pedraza-Echevarría M; Pizzuto-Chávez J
    Arch Med Res; 2003; 34(2):120-3. PubMed ID: 12700007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients.
    Freedman J; Gafni A; Garvey MB; Blanchette V
    Transfusion; 1989; 29(3):201-7. PubMed ID: 2493693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.